Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Steven King Named as Prospective CEO of EdgePoint AI
Brings over 20 years of experience in drug development and pharmaceutical manufacturing, as well as Nasdaq listed public company experience EdgePoint AI is to commercialize TrustPoint AI artificial intelligence driven vision fabric/blockchain technology for pharmaceutical manufacturing Closing of
View HTML
Toggle Summary Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
AGOURA HILLS, Calif. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN, “Mateon”) dedicated to the development of innovative treatments for cancer, announced today the publication of two peer-reviewed expert
View HTML
Toggle Summary Mateon Therapeutics to Present New and Updated Data for OT101 (Trabedersen) Activity Against Brain Tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
AGOURA HILLS, Calif. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, today announced that it will present data updates regarding the anti-brain
View HTML
Toggle Summary Mateon completes its acquisition of PointR Data Inc.
Forms AI Driven Late Clinical-Stage Cancer Immunotherapy Company Focusing on TGF-β RNA Therapeutics in Rare Pediatric Diseases SANTA CLARA, Calif. and AGOURA HILLS, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN)  (‘Mateon”) announced today that they have completed
View HTML
Toggle Summary New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor
AGOURA HILLS, Calif. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today the publication of a peer-reviewed research article authored by
View HTML
Toggle Summary FDA Grants Pediatric Disease Designation for Mateon’s OT101
For treatment of diffuse intrinsic pontine glioma (DIPG), a difficult to treat form of childhood brain tumor AGOURA HILLS, Calif. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration ( FDA ) granted Rare Pediatric
View HTML
Toggle Summary Mateon Partners With WideTrial for Data-Generating Expanded Access Programs in Cancer
AGOURA HILLS, Calif. and SAN FRANCISCO , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN), announced today that it has executed agreements with WideTrial Inc. for an Expanded Access program (EAP) in pancreatic cancer.  Using WideTrial’s novel platform, the investigational
View HTML
Toggle Summary Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer
AGOURA HILLS, Calif. and SANTA CLARA, Calif. , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) and PointR Data Inc. (PointR), a privately-held, developer of high performance cluster computer and artificial intelligence company, announced today that they have
View HTML
Toggle Summary Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing
AGOURA HILLS, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to the development of innovative treatments for cancer, announced today that its team members will participate and provide clinical
View HTML
Toggle Summary Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
AGOURA HILLS, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to development of innovative treatments for cancer, announced today that Dr. John H. Sampson , an internationally recognized
View HTML